FDA Approves Olaparib as Maintenance Therapy for Recurrent Ovarian Cancer

FDA has granted regular approval to olaparib tablets (Lynparza®) as maintenance treatment for patients with recurrent ovarian cancer who are having partial or complete responses to platinum-based chemotherapy.

Cancer Currents: An NCI Cancer Research Blog